CJC/IPAMORELIN

CJC-1295 / Ipamorelin – Research Compound Description

CJC-1295 and Ipamorelin are synthetic research peptides commonly studied in combination for their role in growth hormone (GH) release pathways. Each compound acts through a distinct mechanism, making the pairing of interest in advanced endocrine and metabolic research.

CJC-1295 is a growth hormone–releasing hormone (GHRH) analog studied for its ability to stimulate sustained GH signaling via the pituitary gland. Ipamorelin is a selective ghrelin (GHS-R) receptor agonist, researched for its role in promoting pulsatile GH release with minimal interaction with other hormonal pathways.

When studied together, CJC-1295 and Ipamorelin are of interest for research into synergistic GH signaling, receptor coordination, and downstream physiological processes related to growth hormone activity.

Key Research Focus Areas

• Growth hormone secretion and regulation

• Endocrine signaling pathway research

• Metabolic and cellular regeneration studies

• Peptide synergy and receptor interaction analysis

Compound Characteristics

• Peptide Class: GHRH analog (CJC-1295) & GHS-R agonist (Ipamorelin)

• Primary Targets: GHRH receptors, Ghrelin (GHS-R) receptors

• Research Use: Laboratory and scientific research only

Important Notice

CJC-1295 and Ipamorelin are intended strictly for research purposes only. These compounds are not approved for human or veterinary use and are not intended for consumption, diagnosis, treatment, or prevention of any medical condition.

All research involving these peptides should be conducted by qualified professionals in controlled laboratory environments and in accordance with applicable laws and regulations.